

OUR MISSION

# MARCH OF DIMES LEADS THE FIGHT FOR THE HEALTH OF ALL MOMS AND BABIES.



---

---

---

---

---

---

---

---

## TOO MANY TRENDS IN THE WRONG DIRECTION

PRETERM BIRTH RATES  
have risen for 3 consecutive years

INFANT MORTALITY RATES  
unacceptably high in many communities

OPIOID EXPOSURE rising among  
newborns

STARK DISPARITIES in maternal-child  
outcomes among African American  
women and babies



---

---

---

---

---

---

---

---

OUR CURRENT FOCUS


## THE MATERNAL HEALTH CRISIS

OVER 700 WOMEN die in the US  
each year from complications related to  
childbirth.

2 WOMEN will die from childbirth in the  
US today. And every day.

50,000 WOMEN in the US suffer life-  
threatening complications every year  
during pregnancy.

WOMEN OF COLOR share over 3X  
more likely than white women to die from  
pregnancy-related causes.



#BlanketChange

---

---

---


---

---

---

---

---




---

---

---

---

---

---


---

---

### CT 17P/LOW DOSE ASPIRIN CPQC WORKGROUP

- Chris Nold, MD – Hartford Health Care (HHC)
- Beth Deckers, MD – HHC
- Erica Hammer, MD – HHC
- Veronica Pimentel, MD – St. Francis
- Mary Beth Janicki, MD – St. Francis
- Shefali Pathy, MD – Yale New Haven Health (YNHH)
- Doreen Picagli, DNP, APRN – Yale Women's Health Center
- Jordana Frost, DrPH, MPH – March of Dimes
- Chris Morosky, MD - UCONN Health & Co-Chair of Connecticut Perinatal Quality Collaborative (CPQC)\*

\* CPQC is staffed and administered by Connecticut Hospital Association (CHA)

 MARCH OF DIMES

---

---

---

---

---

---


---


---

### Connecticut Perinatal Quality Collaborative

An initiative of the Connecticut Hospital Association, focused on:

- Promoting high quality maternal and newborn care
- Cooperation between hospitals and providers
- Supporting evidence-based practices
- Sharing educational and training resources
- Gathering critical data





---

---

---

---

---

---

---

---

## CT ACTIVITIES THUS FAR

- 2015 – March of Dimes issued Prematurity Prevention Intervention Roadmap, which included 17P and Low Dose Aspirin
- Spring 2017 – Developed workgroup as part of CPQC
- Fall 2017 – Collected provider survey responses
- Jan. 2018 – Hosted provider educational conference through CPQC
- Nov. 2018 – Participated in regional convener meeting (CT, MA, RI, NY) hosted by March of Dimes



7

---

---

---

---

---

---

---

---

LOW DOSE ASPIRIN FOR  
PREVENTION OF  
PREECLAMPSIA AND WOMEN'S  
CARDIAC HEALTH REGIONAL  
CONVENER

NOVEMBER 27<sup>TH</sup> 2018  
BURLINGTON, MA

CT, MA, NY, RI




---

---

---

---

---

---

---

---

## CARDIOVASCULAR DISEASE IN PREGNANCY

Dr. Nandita Scott, MD, FACC  
Co-Director - MGH Corrigan Women's Heart Health Program  
Cardiovascular Disease and Pregnancy Program

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---


---

## Background

- As maternal age advances, preexisting heart conditions more likely
- Rise in multifetal pregnancies
- Increase in obesity and diabetes in population increase risk of CV complications during pregnancy
- Patients with congenital heart disease are surviving to reproductive age
- Childhood cancer survivors with cardiotoxic effects from therapy



## Normal Hemodynamics of Pregnancy



Yucel E, DeFaria Yeh D. Curr Treat options CardioMed 2017



## How to Risk Stratify



PREDICTOR	POINTS
Prior cardiac events or arrhythmias	3
Baseline NYHA III-IV or cyanosis	3
Mechanical valve	3
Ventricular dysfunction	2
High-risk left-sided valve disease/ left ventricular outflow tract obstruction	2
Pulmonary hypertension	2
Coronary artery disease	2
High-risk aorticopathy	2
No prior cardiac intervention	1
Late pregnancy assessment	1

Risk of Primary Cardiac Event:

0-1 – 5%

2 – 10%

3 – 15%

4 – 22%

> 4 – 41%



Silverman et al. JACC 2018 71 (21): 2419-2430

Modified WHO Classification of Pregnancy Risk					
	mWHO I	mWHO II	mWHO II-III	mWHO III	mWHO IV
Diagnosis	Mild PS small PDA MVP repaired ASD/VSD/PDA Ecotopy	ASD/VSD Repaired ToF Turner with normal aorta Most arrhythmias	Mild LV EF impairment HCM Native or tissue valve disease not WHO I or IV Marfan without dilatation Aorta < 45 in BAV AVSD Repaired coarctation	Moderate LV systolic dysfunction Prior PPCM with normal LV EF Mechanical valve Fontan circulation Moderate MS Severe AS Moderate Aortic dilatation in Marfan or BAV VT Systemic RV Unrepaired cyanotic	PAH LV EF < 30% Prior PPCM with impairment Severe MS Severe symptomatic AS Systemic RV with moderate or more impairment Severe aortic dilatation Vascular EDS Severe coarctation Fontan with any complication
Mortality Risk	None	Small increase	Intermediate	Significant increased	Extremely high
Morbidity Risk	No/mild	Moderate	Moderate to severe	Severe	Severe
Maternal cardiac event rate	2.5 – 5%	5.7-10.5%	10-19%	19-27%	40-100%
Care During Pregnancy	Local	Local	Referral hospital	Expert center	Expert center
Followup	Once or twice	Once per trimester	Bimonthly	Monthly or bimonthly	Monthly

## Mode of Delivery

- Vaginal delivery remains optimal method of delivery
- Cesarean section increases risk of maternal infection, has greater hemodynamic shifts and blood loss, risk of surgical injury and greater risk for thrombotic events
- Option for assisted 2<sup>nd</sup> stage
- No consensus absolute contra indications to vaginal delivery, in a few unique situations, can be considered first
  - preterm labor in the presence of full oral anticoagulation
  - Marfans with aorta over 45 mm
  - Acute or chronic aortic dissection
  - Intractable heart failure



17

## Multidisciplinary Care

- Managing pregnant women with heart disease implicates several stakeholders, all with different perspectives but COMMON goals
- Team should include Cardiologist with expertise, OB anesthesia, Maternal-Fetal Medicine and Nursing
- Meet regularly to discuss, anticipate and plan for any potential difficulties



18




---

---

---

---

---

---

---

---

## Hypertensive Disorders of Pregnancy

- Preeclampsia (5% incidence) can lead to significant pregnancy complications:
 

IUGR	Preterm birth	Hemorrhage
Placental	Ruptured Liver	Eclampsia
Abruption		Renal failure
- Preeclampsia responsible for 50,000 to 60,000 deaths worldwide and there are many near misses that result in significant health risk and care cost
- Preeclampsia is a risk factor for future cardiovascular and neurological disease
- Etiology remains unclear

MASSACHUSETTS  
GENERAL HOSPITAL  
CORRIEN MINERHAN  
HEART CENTER

---

---

---

---

---

---

---

---

## How can we prevent preeclampsia?

**U.S. Preventive Services Task Force**

You are here: Home > Recommendations for Primary Care Practice > Published Recommendations > Draft Summary

### Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Release Date: September 2014

**Recommendation Summary**

**Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia**

Population	Recommendation	Grade (Strength of Recommendation)
Pregnant Women Who Are At High Risk for Preeclampsia	The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.	B

**Supporting Documents**

- Final Evidence Review (PDF Version [PDF icon])
- Final Evidence Summary (PDF Version [PDF icon])

**Read Full Recommendation Statement** (PDF Version [PDF icon])

**Clinical Summary**

Clinical summaries are one-page documents that provide guidance to primary care clinicians for using recommendations in practice. This summary is intended for use by primary care clinicians.

**Related Information for Consumers**

- Low-Dose Aspirin to Prevent Morbidity and Mortality From Preeclampsia: Consumer Guide

**Related Information for Health Professionals**

- Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Clinical Summary of USPSTF

MASSACHUSETTS  
GENERAL HOSPITAL  
CORRIEN MINERHAN  
HEART CENTER

B= high certainty that net benefit is moderate, or moderate certainty that net benefit is moderate to substantial

---

---

---


---

---


---

---

---



The American College of  
Obstetricians and Gynecologists  
WOMEN'S HEALTH CARE PHYSICIANS



Society for  
Maternal-Fetal  
Medicine  
High-Risk Pregnancy Experts

July 2018

## ACOG COMMITTEE OPINION

Number 743


**Committee on Obstetric Practice  
Society for Maternal-Fetal Medicine**

This Committee Opinion was developed by the Committee on Obstetric Practice in collaboration with committee member T. Elise Porter, MD, and the Society for Maternal-Fetal Medicine in collaboration with members Cynthia Gyamfi-Bannerman, MD, MS, and Tracy Mamas, MD.

### Low-Dose Aspirin Use During Pregnancy

"Low dose aspirin prophylaxis is **recommended** in women at **high risk** of preeclampsia and should be initiated...optimally before 16 weeks and continued daily until delivery"

"Low dose aspirin prophylaxis should be **considered** for women with **more than one...moderate** risk factor for preeclampsia"



MASSACHUSETTS  
GENERAL HOSPITAL  
CORBARIAN-MINERHAN  
HEART CENTER

---

---

---

---

---

---

---

---

---

---

Who should receive low dose aspirin?		
Risk Level	Risk Factors	Recommendation
High	History of Preeclampsia	Low dose aspirin if any one of these risk factors
	Multifetal gestation	
	Chronic hypertension	
	Diabetes	
	Renal disease	
	Autoimmune disease	
Moderate	Nulliparity	Low dose aspirin if "several" of these risk factors
	Obesity	
	Family history (mother, sister)	
	Socio economic factors	
	Age ≥ 35 Personal history( low birthweight or SGA, prior adverse pregnancy outcome, interpregnancy interval > 10 years	
Low	Previous uncomplicated full term delivery	Do not recommend low dose aspirin

---

---

---

---

---


---

---

---

---

---



## THE BOSTON MEDICAL CENTER PRENATAL ASPIRIN PROJECT

Dr. Jodi Abbott, MD, MSc, MHCM  
Asst. Dean for Patient Safety and Quality Improvement  
Boston Medical Center (BMC)

---

---

---

---

---

---

---

---

---

---



## Epidemiology

### National

- Preeclampsia in 2-5% of all pregnancies in the U.S.
- Leading cause of maternal morbidity and up to 19% maternal mortality
- Rates of hypertension in pregnancy are increasing

### BMC

- Approximately 30% of pregnancies complicated by preeclampsia/ Gestational HTN and/or IUGR
- Approximately 40% of preterm births are due to preeclampsia/ Gestational HTN and/or IUGR

---

---

---

---

---

---

---

---

## Epidemiology

### National

- Preeclampsia in 2-5% of all pregnancies in the U.S.
- Leading cause of maternal morbidity and up to 19% maternal mortality
- Rates of hypertension in pregnancy are increasing

### BMC

- Approximately 30% of pregnancies complicated by preeclampsia/ Gestational HTN and/or IUGR
- Approximately 40% of preterm births are due to preeclampsia/ Gestational HTN and/or IUGR

33%

40%

---

---

---

---

---

---

---

---

Journal List > J R Soc Med > v.104(12); 2011 Dec > PMC3241518



J.R.Soc.Med. 2011 Dec; 104(12): 510-520.  
doi: 10.1258/jrsm.2011.110180

PMCID: PMC3241518

### The answer is 17 years, what is the question: understanding time lags in translational research

Zoë Slote Morris,<sup>1</sup> Steven Wooding,<sup>2</sup> and Jonathan Grant<sup>2</sup>

Author information ► Copyright and License information ►

See editorial "Knowledge lost in translation" in volume 104 on page 487.

This article has been cited by other articles in PMC.

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---



**Cochrane**  
Effective Practice and  
Organisation of Care

Trusted evidence.  
Informed decisions.  
Better health.

### Classification of Professional interventions

- DISTRIBUTION OF EDUCATIONAL MATERIALS
- EDUCATIONAL MEETINGS
- LOCAL CONSENSUS PROSESSES
- LOCAL OPINION LEADERS
- PATIENT MEDIATED INTERVENTIONS; NEW INFORMATION FROM PATIENT COLLECTED INFORMATION
- AUDIT AND FEEDBACK
- REMINDERS (PROMPTS)
- MARKETING
- MASS MEDIA

EPOC TAXONOMY: Cochrane Effective Practice and Organization of Care

---

---

---


---

---

---

---

---



**Cochrane**  
Effective Practice and  
Organisation of Care

Trusted evidence.  
Informed decisions.  
Better health.

### Classification of Professional interventions

►DIST  
►EDU  
►LOC  
►LOC  
►PAT  
►INFO  
►AUD  
►REM  
►MAR  
►MASS

**Most Effective:**

**HARD STOPS IN THE EHR**

**AUDIT AND FEEDBACK**

EPOC TAXONOMY: Cochrane Effective Practice and Organization of Care

---

---

---

---

---

---

---

---

### Preeclampsia, gHTN, and/or IUGR in current pregnancy

- 83 cases of the following:
  - 24 cases of preeclampsia
  - 37 cases of gHTN
  - 24 cases of IUGR
- 79 of these patients qualified for PNA

**60% patients had complications that were potentially preventable if on prenatal aspirin**

**71% of qualified pts with IUGR and/or preeclampsia or gHTN were *not* on Prenatal Aspirin**

---

---

---

---

---


---

---

---


## Patient Survey Data

### % of surveyed about aspirin safety in pregnancy?



Language	Safe	Not Safe	Not Sure
English	9	29	12
Spanish	2	17	0
Grand Total	11	46	12

### Causes of “aspirin in pregnancy-is-unsafe” preconceived notions



### What the patient (and pharmacist) sees




---

---

---

---

---

---

---

---

---

---

### Pharmacist Survey Data

---

---

---

---

---

---

---

---

---

---

### Two Pharmacist Surveys

- ▶Survey of Pharmacists at BMC
- ▶(n=22)
- ▶Staff working at the outpatient pharmacies in the hospital
- ▶The survey, conducted via email using SurveyMonkey, was sent to 26 staff and 22 responded, which included a mix of both pharmacists and pharmacy technicians.
- ▶MA Pharmacists Needs Assessment Survey
- ▶Sent out to over 4,000 pharmacists in New England, and 50 responded
- ▶The majority of respondents reported working in a hospital inpatient or outpatient pharmacy (48.9%), 22.4% in a community pharmacy, 14.2% in ambulatory care, and 12.2% in Other.
- ▶Most pharmacists had been in practice for 21+ years (48.9%), between 11 and 20 years (22.4%), and between 0 and 5 years (20.4%).

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---


---

---


## Pharmacist Intervention

Most effective way to reach pharmacists is to:

- Recruit pharmacy liaisons
- Attend, present, and table at pharmacy conferences
- Pass on all of our educational materials



## Stakeholder Directed Implementations



## Sample of Education Materials

### What You Need To Know: Aspirin in Pregnancy

- It's also known as *low-dose, baby, prenatal, or 81mg aspirin*
- For 30 years research has shown that prenatal aspirin has many benefits.
  - It does not harm mom or baby.\*

#### Benefits of prenatal aspirin:


- It is safe to use in pregnancy
- Works within the placenta
- Helpful for both you and your baby
- Lowers your chance of a premature baby
- Lowers your chance of a low birth-weight baby

#### Side effects or risks of prenatal aspirin:

- Will not cause you to have increased bleeding
- Does not reach the baby's blood, has not been shown to have negative effects on the baby's initial development
- Does not increase risk of miscarriage
- Does not need to be stopped before delivery



Reference: Ili Henderson, et al. Low-Dose Aspirin for the Prevention of Preterm Birth and Maternal Mortality: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 112. AHRQ Publication No. 14-02307-01-1. Rockville, MD: Agency for Healthcare Research and Quality; 2014.




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---


---

---

---

---





### CPQC Provider Survey 2017-2018

- Survey Monkey and in-person paper surveys
- CPQC list-serv and local resources
- Provider practices and beliefs related to Low Dose Aspirin (LDA) and 17-OH progesterone (17P)
- Rolled out October 2017 – January 2018
- n = 163 total survey respondents

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---



Open Comments

- "Advocate pharmacy staff that this is safe and recommended in pregnancy."
- "Many patients are hesitant about safety. Advocacy in pharmacies would be helpful."
- "Signs at the pharmacy."
- "Public service announcements."

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## Strategy for Postpartum Hypertension

- During the postpartum period, there are marked cardiovascular and hemodynamic shifts
- There are few standardized approaches for identification and management of women most at risk for postpartum hypertensive complications leading to variability in practice
- Opportunities for inequities in care
  - practitioners vulnerable to management errors
  - women at risk of harm

58

## Strategy for Postpartum Hypertension

- ACOG provides detailed protocols for management of severe and acute hypertension during pregnancy
- There are no specific guidelines for the initiation of antihypertensive medications in the postpartum period for women with blood pressure elevations that are not severe.
- MGH Plan: Electronically-Integrated Management Strategy in women with hypertension or preeclampsia post partum

59

## What we can do about history of preeclampsia?

### RESEARCH

www.AJOG.org

#### OBSTETRICS

### The maternal health clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications

Maria C. Castanos, MD, Jessica Paduelli, MPH, Michelle Roddy, RN, BSN, Chen Kyoung Jane Cho, PhD, Giovanni R. Smith, MD, PhD

**OBJECTIVE:** Women who develop certain common pregnancy complications have a greater chance of developing cardiovascular disease (CVD) later in life. However, most health care providers do not provide postpartum cardiovascular risk counseling or follow-up. The Maternal Health Clinic was established to address this gap in care. It targets women at increased risk of CVD to improve lifestyle changes, encourage long-term follow-up, and initiate primary prevention. Here, we summarize results from the first 17 months of completed data.

**STUDY DESIGN:** Patients experiencing at least one relevant complication in their index pregnancy were referred to the Maternal Health Clinic through standard postpartum order sheets. Patients underwent a complete assessment including screening history, physical examination, fasting bloodwork, and analysis. Lifetime and 30-year CVD risk estimates, along with a metabolic syndrome calculation, were determined for each patient.

**RESULTS:** Complications most commonly leading to referral were gestational diabetes or impaired glucose tolerance (52.7%), preeclampsia (27.7%), antenatal death (25.2%), and gestational hypertension (19.6%). The clinic analysis group ( $n = 103$ ) was compared with a healthy control group from the Multicenter Newborn Study (Study II-118). Patients in the clinic analysis group had significantly increased lifetime and 30-year CVD risk estimates compared with healthy controls ( $P < .0001$ ). Furthermore, 17.4% of the clinic analysis group had metabolic syndrome compared with 0.7% of healthy controls ( $P < .01$ ).

**CONCLUSION:** This study demonstrates that the Maternal Health Clinic accurately identifies postpartum patients that have underlying cardiovascular risk which make them susceptible to CVD. The clinic may serve as an effective primary prevention strategy.

**Key words:** cardiovascular disease, maternal health clinic, pregnancy, pregnancy complications, risk factor

Cite this article as: Castanos MC, Paduelli J, Roddy M, et al. The Maternal Health Clinic: an initiative for cardiovascular risk identification in women with pregnancy-related complications. Am J Obstet Gynecol 2018;219:638.e1-6.

60

**Brigham and Women's Hospital  
Cardiometabolic Clinic in  
Maternal Fetal Medicine  
2011-present**

Ann C. Celi MD, MPH  
Assistant Professor Harvard Medical School  
Division of General Medicine and Primary Care,  
Department of Medicine, Brigham and Women's Hospital

---

---

---

---

---

---

---

---

**BWH Cardiometabolic Clinic in MFM  
Thursday mornings 732-4840**

Clinical Care for Postpartum women with complex  
hypertensive pregnancies

- started October 2011
- >600 patients seen and followed

Louise Wilkins-Haug MD, PhD- Maternal Fetal  
Medicine  
Ann Celi MD, MPH – Primary Care Medicine

---

---

---

---

---

---

---

---

**BWH Cardiometabolic Clinic Design**

- Early postpartum hypertension medical management
- Patient and provider education around cardiovascular risk
- Clinical bridge with primary obstetric and medicine providers
- Sustainable clinical model reimbursed by private and public insurances

---

---

---

---

---

---

---

---

## Innovations

- **Blood pressure monitors**
- **Medical Home and Primary Care**
- **Breastfeeding education/support:** includes compatibility of medications
- **Contraception counseling** informed by complex pregnancy/delivery and hypertension history
- **Resources** including housing, WIC, food stamps, summer camp, Globe Santa
- **Nutrition** to optimize heart healthy lifestyle
- **Paternal leave** to help care for maternal and infant medical issues
- **Maternal leave** and transition back to work.
- **Community engagement-** family, friends, church to provide additional help after complex pregnancy

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

## CT OPPORTUNITIES

- Greater coordination of care throughout the life course, and particularly before, during, and after/between pregnancies
  - Women's health care providers (gynecology, obstetrics, midwifery)
  - Primary care providers (internal medicine and pediatrics)
  - Family medicine providers
  - EMR changes? Patient advocates/navigators? Special Postpartum Clinics? Digital BP cuffs?
  - Paid family medical leave?

---

---

---

---

---

---

---

---

## CT OPPORTUNITIES

### ➤ Patient education

- Acceptability and tailored messaging
- Patient education handout (MOD→ HH)
- Patient education video clips (DPH)
- CHNCT perinatal intensive care management program?

### ➤ Clinical provider education and quality measures

- Traveling grand rounds (CPQC workgroup)
  - Effectiveness, safety, indications, Medicaid OTC coverage
- Video? Podcast episode? (DPH)
- Uniform screening
- OB P4P?



67

---

---

---

---

---

---

---

---

## CT OPPORTUNITIES (CONT'D)

### ➤ Pharmacy professional education

- Professional association conferences & meetings?
- Partnership with major pharmaceutical companies (CVS, Walgreens, Walmart, RiteAid, etc.)?

### ➤ Pharmaceutical labeling

- "Prenatal aspirin" (PNA)?

### ➤ Public health approaches to chronic disease prevention, pre-/interconception health, and pregnancy intentionality



68

---

---

---

---


---

---

---

---

**Video: Visit [www.prenatalaspirin.com](http://www.prenatalaspirin.com)**




---

---

---

---

---

---

---

---



THANK  
YOU

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---


---

---

---

---






---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---